London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Hikma’s CEO, said: “I am pleased ...

Consisting of five separate booklets, the World Drug Report 2021 provides an in-depth analysis of the global drug markets and paints a comprehensive picture of the measurable effects and potential ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Drug screening is the process by which potential drugs are identified and optimized before selection of a candidate drug to progress to clinical trials. It can involve screening large libraries of ...

This is the most recent version of the national Cancer Drugs Fund list, and replaces any earlier versions. It contains updates to the previous list, as well as new drugs and indications which have ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.